COVID-19: Prof Didier Raoult Releases Results Of Hydroxychloroquine Treatment Study On 1061 Patients
Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens.
Read More
By 2030 India is set to have the largest working-age population in the world.
This knowledge is essential for discerning molecular processes in health and disease.
The system is accessible by any standard internet browser and also from a mobile device.
It seeks to create mass awareness about the need to ethically develop and practice AI.
The vaccine is developed from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune.
Gates Foundation, along with Gavi-The Vaccine Alliance, will provide funding of $150 million to Serum Institute.
Anybody willing to participate in the trial can send an email to [email protected]
This marks the first regulatory approval for India’s domestic vaccine to enter trials.
Ultra Swachh uses an advanced oxidative process by using Ozonated Space Technology for the disinfection process.
FBOT is basically a type of cosmic explosion that was initially detected in the optical wavelength.
It is very important for individuals to not panic and believe in the basic mantra “break the virus chain”.
COVID-19: ICMR-NIV, Pune, Develops ‘Made In India’ ELISA Test Kit For Coronavirus Antibody Detection
The kit has a sensitivity of 98.7 per cent and specificity of 100 per cent on external validation.
It is robotics-enabled that minimizes the chance of contamination and the risk of infection to the health care workers.
ICMR has initiated a multi-centre clinical PLACID trial; 35 institutions have been approved for the trial.
IMD lists Gilgit-Baltistan, Muzaffarabad under J&K meteorological sub-division.
Health experts have long called for wider testing to check for community transmission of COVID-19.
The addition of a suitable polymer will increase the virucidal properties of the hydrophobic nanocoating.
The lab was built in 15 days and can process more than 1,000-2,000 samples in a day.
The genomic resource obtained from this sequencing will enable the identification of new targets for diagnosis and drugs.
Currently, the tests require a swab from deep in the nasal passages or the back of the throat.
Patients with flu symptoms and RT-PCR negative will serve as controls.
The DRDL has developed the COVSACK in consultation with ESIC Hospital, Hyderabad.